- Home
- BNGO vs CVKD Comparison
BNGO vs CVKD Comparison
Compare BNGO & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNGO
- CVKD
- Stock Information
- Founded
- BNGO 2003
- CVKD 2022
- Country
- BNGO United States
- CVKD United States
- Employees
- BNGO N/A
- CVKD N/A
- Industry
- BNGO Biotechnology: Laboratory Analytical Instruments
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- BNGO Industrials
- CVKD Health Care
- Exchange
- BNGO Nasdaq
- CVKD Nasdaq
- Market Cap
- BNGO 24.3M
- CVKD 27.0M
- IPO Year
- BNGO 2018
- CVKD 2023
- Fundamental
- Price
- BNGO $1.72
- CVKD $13.49
- Analyst Decision
- BNGO Buy
- CVKD Strong Buy
- Analyst Count
- BNGO 4
- CVKD 1
- Target Price
- BNGO $7.67
- CVKD $32.00
- AVG Volume (30 Days)
- BNGO 428.1K
- CVKD 25.3K
- Earning Date
- BNGO 11-13-2025
- CVKD 11-07-2025
- Dividend Yield
- BNGO N/A
- CVKD N/A
- EPS Growth
- BNGO N/A
- CVKD N/A
- EPS
- BNGO N/A
- CVKD N/A
- Revenue
- BNGO $27,426,000.00
- CVKD N/A
- Revenue This Year
- BNGO N/A
- CVKD N/A
- Revenue Next Year
- BNGO $24.54
- CVKD N/A
- P/E Ratio
- BNGO N/A
- CVKD N/A
- Revenue Growth
- BNGO N/A
- CVKD N/A
- 52 Week Low
- BNGO $1.50
- CVKD $8.74
- 52 Week High
- BNGO $22.80
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- BNGO 34.85
- CVKD 50.95
- Support Level
- BNGO $1.85
- CVKD $12.71
- Resistance Level
- BNGO $1.85
- CVKD $13.75
- Average True Range (ATR)
- BNGO 0.08
- CVKD 0.78
- MACD
- BNGO 0.02
- CVKD -0.04
- Stochastic Oscillator
- BNGO 2.25
- CVKD 61.61
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.